Research on non-small cell lung cancer is ongoing, with studies focusing on various aspects such as diagnostics, treatment strategies, and molecular pathology. The role of MET diagnostics is being explored, and companies like Lunit and Caris Life Sciences are involved in efforts to advance precision oncology and provide testing for non-small cell lung cancer patients. Multiple studies, including those on genomic profiles and multi-omics, are aiming to refine treatment approaches for this type of cancer.